Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Year: March 06, 2025